Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 32 citing articles:

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Fumou Sun, Yan Cheng, Visanu Wanchai, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 17
Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma
Kevin Reyes, Yen‐Chun Liu, Chiung‐Yu Huang, et al.
Blood Advances (2024) Vol. 8, Iss. 9, pp. 2207-2216
Open Access | Times Cited: 12
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Zhaoyun Liu, Wenhui Lei, Hao Wang, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access | Times Cited: 1
Checkpoint CD24 function on tumor and immunotherapy
Shiming Huang, Xiaobo Zhang, Yingtian Wei, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Meera Mohan, Oliver Van Oekelen, Othman Salim Akhtar, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 7
DRMref: comprehensive reference map of drug resistance mechanisms in human cancer
Xiaona Liu, Jiahao Yi, Tina Li, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1253-D1264
Open Access | Times Cited: 13
Therapeutic progress in relapsed/refractory multiple myeloma
Qi Chen, Min Zhang, Shan Zheng, et al.
Annals of Hematology (2024) Vol. 103, Iss. 6, pp. 1833-1841
Closed Access | Times Cited: 5
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐BCMA CAR T‐cell‐based therapy
Yuekun Qi, Hujun Li, Kunming Qi, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 12, pp. 2286-2295
Open Access | Times Cited: 5
Targeting GPRC5D in multiple myeloma
Shatha Elemian, Samer Al Hadidi
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 5, pp. 229-238
Closed Access | Times Cited: 4
DrugFormer: Graph‐Enhanced Language Model to Predict Drug Sensitivity
Xiaona Liu, Qing Wang, Minghao Zhou, et al.
Advanced Science (2024) Vol. 11, Iss. 40
Open Access | Times Cited: 4
Targeting GPRC5D for multiple myeloma therapy
Dian Zhou, Ying Wang, Chong Chen, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma
Josephine G. M. Strijker, Guillem Pascual‐Pasto, Grant Grothusen, et al.
European Journal of Cancer (2025), pp. 115263-115263
Open Access
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Susanna Kim, Adam ElSayed, Jonathan E. Moore, et al.
Targeted Oncology (2025)
Closed Access
Targeting BCMA in multiple myeloma: designs, challenges, and future directions
Yi Hu, Yuetao Xie, Xiaodong Wang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access
Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?
Yunhui Xiang, Guokang Sun, Lvbo Tian, et al.
Annals of Hematology (2025)
Open Access
CAR-T for multiple myeloma: practice pearls
Daniel O'Leary, Veronika Bachanová
Bone Marrow Transplantation (2025)
Closed Access
Innovative prognostic modeling in ESCC: leveraging scRNA-seq and bulk-RNA for dendritic cell heterogeneity analysis
Mengnan Shi, Han Zhang, Linnan Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets
Yanpeng Wang, Yuanliang Peng, Chaoying Yang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 9
Open Access | Times Cited: 3
The Simple prEservatioN of Single cElls method for cryopreservation enables the generation of single-cell immune profiles from whole blood
Sarthak Satpathy, Beena Thomas, William Pilcher, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
Bingjie Fu, Rui Liu, Gongzhizi Gao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
Jingjing Pu, Ting Liu, Amit Sharma, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 2
Clinical outcomes and microenvironment profiling of relapsed/refractory extramedullary disease of multiple myeloma patients with anti-BCMA CAR T cell-based therapy
Yuekun Qi, Hujun Li, Kunming Qi, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Single-cell genomics-based immune and disease monitoring in blood malignancies
Anja C. Rathgeber, Leif S. Ludwig, Livius Penter
Clinical Hematology International (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 1
Advancements in the design and function of bispecific CAR-T cells targeting B Cell-Associated tumor antigens
Helin Sima, Wenwei Shao
International Immunopharmacology (2024) Vol. 142, pp. 113166-113166
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top